A Study of QL1604 Plus Nab-paclitaxel Versus Paclitaxel in Subjects With Advanced Gastric Cancer.

Advanced Gastric or Gastroesophageal Junction Adenocarcinoma Clinical Trial

Official title:
A Study of QL1604 Plus Nab-paclitaxel Versus Paclitaxel for Participants With Advanced Gastric or Gastroesophageal Junction Adenocarcinoma That Progressed After Therapy With Platinum and Fluoropyrimidine

Status Not yet recruiting

Clinical Trial Summary

This is a study for participants with advanced gastric or gastroesophageal junction adenocarcinoma who had tumor progression after first-line treatment with platinum and fluoropyrimidine doublet therapy. The study will be conducted in 2 parts.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Adenocarcinoma
Advanced Gastric or Gastroesophageal Junction Adenocarcinoma
Esophageal Neoplasms

Clinical Trial Details

NCT number	NCT04435652
Study type	Interventional
Source	Qilu Pharmaceutical Co., Ltd.
Contact	Shunjiang Yu, CMO
Phone	0531-83129659
Email	shunjiang.yu@qilu-pharma.com
Status	Not yet recruiting
Phase	Phase 2/Phase 3
Start date	July 1, 2020
Completion date	November 30, 2022

View Details

See also
	Status	Clinical Trial	Phase
	Completed	`NCT02426034` - A Study of Apatinib Tablets in the Treatment of Advanced or Metastatic Gastric Cancer	Phase 4
	Recruiting	`NCT05585580` - Second-line Treatment With Serplulimab, Lenvatinib, and Paclitaxel in Advanced Gastric Cancer After Prior Immunotherapy	Phase 2